Viralytics on track with IV delivery
Wednesday, 25 June, 2008
Viralytics (ASX: VLA) has completed the first step of phase I clinical trials of its oncolytic virus technology, Cavatrak, for stage IV metastatic melanoma.
The safety trial involved each subject receiving an intravenous injection of Cavatrak. No adverse effects were found in the test subjects, the company said.
Viralytics has also been granted clearance to continue the trials with the next patient group. This cohort will receive two injections of the drug seven days apart.
This trial is being run concurrently with another set of clinical trials of late-stage melanoma patients. The subjects in that trial are being given multiple intra-tumoural injections of Cavatrak in doses up to 100 times the original.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
